Deals in Depth: August 2010
Executive Summary
Disclosed pre-commercial potential deal values in pharma alliances were on the low side in August - topping the list at only $80 million was Biogen Idec's license to Knopp's Phase II ALS candidate. Life Technologies gained more DNA sequencing tools through its $375 million buy of Ion Torrent Systems in a transaction that also includes $350 million in earn-outs. Pharma financing was up 20% from July, while device company fund-raising was down by more than half.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.